Optimization of Levomilnacipran Loaded Nanostructured Lipid Carrier Using Response Surface Methodology

Area of Science:

• Pharmaceutical Sciences
• Nanotechnology
• Drug Delivery Systems

Background:

• Levomilnacipran is a serotonin-norepinephrine reuptake inhibitor used for treating depression.
• Nanostructured lipid carriers (NLCs) offer a promising platform for improving drug solubility, stability, and controlled release.
• Optimizing NLC formulations is crucial for maximizing therapeutic efficacy and patient compliance.

Purpose of the Study:

• To optimize the formulation of Levomilnacipran-loaded nanostructured lipid carriers (LEV-NLCs).
• To investigate the impact of key formulation variables on LEV-NLC characteristics.
• To evaluate the in vitro release profile of optimized LEV-NLCs.

Main Methods:

• Response Surface Methodology (RSM) with a Central Composite Rotatable Design (CCRD) was employed.
• Three independent variables were studied: aqueous to organic phase ratio (X1), drug to lipid ratio (X2), and surfactant concentration (X3).
• Particle size, zeta potential, and entrapment efficiency were measured; morphology was assessed by SEM and TEM; drug release was studied at pH 7.4 and 6.0.

Main Results:

• RSM successfully optimized LEV-NLC formulation parameters.
• The optimal formulation comprised a 1:1 aqueous to organic phase ratio, a 1:7 drug to lipid ratio, and 0.5% surfactant concentration.
• Optimized LEV-NLC exhibited a particle size of 148 nm, zeta potential of 36 mV, entrapment efficiency of 88%, spherical morphology, and sustained release (77% at pH 7.4, 76% at pH 6.0 over 24 hours).

Conclusions:

• RSM-CCRD is an effective tool for modeling and optimizing LEV-NLC formulations.
• The optimized LEV-NLC formulation demonstrates potential for enhanced Levomilnacipran delivery.
• The sustained release profile suggests improved therapeutic benefits and reduced dosing frequency.